Buy Visomitin (SkQ1) 5ml
Active ingredient: Plastoquinonyldecyltriphenylphosphonium bromide
1 bottle x 5ml
A few years ago a small molecule SkQ1 was synthesized by the group of professor Vladimir P. Skulachev in the Moscow State University. One part of SkQ1 functions as a molecular “tow truck” carrying the other part of the molecule – an extremely active antioxidant plastoquinone – into mitochondria. Both theoretical calculations and experimental results showed that SkQ1 was delivered into the mitochondria in an extremely targeted and efficient manner. The physics of the mitochondrial membrane and the unique properties of SkQ1 direct it into the inner leaflet of the inner mitochondrial membrane with high precision.
The presence of SkQ1 in mitochondrial membrane enables mitochondria to protect itself from reactive oxygen species (ROS) by breaking the chain reaction of lipid destruction. This ability of the lead molecule to protect cells against oxidative stress is the such as cardiovascular diseases, neurodegenerative disorders and ophthalmic conditions.
It has been hypothesized that age-dependent accumulation of oxidative damages in living organisms may be the main cause of ageing process. It might be possible to control this damage accumulation through controlling the level of ROS production in mitochondria. It is important to stress that ROS production should be controlled, not stopped, so that ROS can still fulfill a number of crucial biological functions. For instance they fight bacteria and viruses, both directly – via elimination of pathogens, – and indirectly – via regulation of the immunological response to infection through triggering apoptosis (cell death).
Antioxidants are a well−developed pharmacological approach to fight against ROS. A possible role of antioxidants in controlling ageing process has widely and for a long time been discussed with ambiguous conclusions, ranging from the statement of the American biochemist Prof. Bruce Ames and colleagues on finding a new anti−ageing therapy with a 100% positive result to D. Howes’s implication of the utter barrenness of this method, and, therefore, of total failure of Harman’s “free radical” hypothesis. According to Dr. Skulachev the antioxidant−based ageing control approach has some significant flaws.
The “ideal” antioxidant should be specifically targeted to mitochondria where ROS are produced and it should effectively remove not all the ROS but just their excess. It is also important for an antioxidant not to be toxic and not to be recognized and eliminated by cell enzymes.
With these criteria fulfilled, a successful anti-oxidant compound should be able to prevent/repair oxidative damage in organism and prevent/treat many age-related disorders across various therapeutic areas.
of SkQ1 involves at least two extremely complex and novel concepts: delivering a compound inside mitochondria and reducing ROS production inside mitochondria in a controlled and sustainable manner. SkQ1 molecule successfully addresses these two aspects as our experimental work has shown.
More than a dozen studies have been conducted and showed SkQ1 effectiveness in such :
o Age-related macular degeneration (AMD)
o Dry eye syndrome (DES)
o Non-infectious uveitis
One of the reasons for the development of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photo-oxidation processes, leading to denaturation of the main structural component of the lens - crystallins. The first protection of eye tissue from ultraviolet radiation is tear fluid, which absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of the tear fluid. According to preclinical studies, the anti-cataract effect of Vizomitin® is associated with an increase in the level of expression of the main proteins of? -Crystalline lenses, restoration of the lens epithelium and activation of energy processes in it. According to a clinical study, patients with age-related cataracts who used Vizomitin® had an increase in the antioxidant activity of tears.
Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of treatment is determined by the doctor depending on the severity of the disease. The initial stage of age-related cataracts: 1-2 drops of the drug in the conjunctival sac 3 times a day. Duration of treatment is 6 months. During drug therapy, an ophthalmologist should be monitored to assess the degree of disease progression and the need to continue conservative therapy.
Data on overdose for local use are not available.
VISOMITIN EYE DROPS SkQ1 5ml
- Product Code: SkQ1-5
- Availability: In Stock
- Ex Tax: $29.82